Abstract
Flavopiridol is currently under consideration as a parenteral treatment of breast tumors. The solubility of this poorly water-soluble compound can be increased by a number of methods. However, because of its low water solubility, precipitation of the solubilized drug upon injection can be a problem. The potential of several flavopiridol formulations to precipitate is evaluated using a static serial dilution technique. It is shown that formulations containing up to 10 mg/mL of flavopiridol which produce negligible precipitation on dilution can be developed.
Footnotes
- Received September 14, 1998.
- Accepted December 30, 1998.
- Copyright © Parenteral Drug Association. All rights reserved.
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.
